Inhibition of pancreatic cancer cell growth

Cellular and Molecular Life Sciences

Volumn 64, Issue 19-20, 2007, Pages 2512-2521

  Adrian, T E ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Apoptosis; Growth inhibition; Pancreatic cancer

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BRYOSTATIN 1; CASPASE INHIBITOR; CETUXIMAB; CYCLOOXYGENASE 1 INHIBITOR; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GABEXATE MESILATE; GAMMA INTERFERON; GEMCITABINE; GENISTEIN; GLIOTOXIN; GN 963; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MATUZUMAB; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PHYTOALEXIN; PROTEIN TYROSINE KINASE INHIBITOR; RESVERATROL; SALAZOSULFAPYRIDINE; SURVIVIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; WORTMANNIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; DRUG RESEARCH; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; HUMANS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 35648940269     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-007-7072-4     Document Type: Short Survey

References (84)

1. Cardenes, H. R., Chiorean, E. G., DeWitt, J., Schmidt, M. and Loehrer, P. (2006) Locally advanced pancreatic cancer: Current therapeutic approach. Ocologist 11, 612-623.
2. Carpelan-Holmstrçm, M., Nordling, S., Pukkala, E., Sankila, R., Lüttges, J., Klçppel, G. and Haglund, C. (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Pancreas 54, 385-387.
3. Giovannetti, E., Mey, V., Nannizzi, S., Pasqualetti, G., Del Tacca, M. and Danesi, R. (2006) Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther. 6, 1387-1395.
4. Nakano, Y., Tanno, S., Koizumi, K., Nishikawa, T., Nakamura, K., Minoguchi, M., Izawa, T., Mizukami, Y., Okumura, T. and Kohgo, Y. (2007) Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer 96, 457-463.
5. Talar-Wojnarowska, R. and Malecka-Panas, E. (2006) Molecular pathogenesis of pancreatic adenocarcinoma: Potential clinical implications. Med. Sci. Monit. 2, RA186-RA193.
6. Schneider, G. and Schmid, R. M. (2003) Genetic alterations in pancreatic carcinoma. Mol. Cancer 2, 15.
7. Okada, H. and Mak, T. W. (200) Pathways of apoptotic and non-apoptotic death in tumor cells. Nat. Rev. Cancer 4, 592-603.
8. Ghobrial, I. M., Witzig, T. E. and Adjei, A. A. (2005) Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178-194.
9. Elnemr, A., Ohta, T., Yachie, A., Kayahara, M., Kitigawa, H., Fujimura, T., Ninomiya, I., Fushida, S., Nishimura, G. I., Shimizu, K. and Miwa, K. (2001) Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int. J. Oncol. 2, 311-316.
10. Matsuzaki, H., Schmied, B. M., Ulrich, A., Standop, J., Schneider, M. B., Batra, S. K., Picha, K. S. and Pour, P. M. (2001) Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin. Cancer Res. 2, 407-414.
11. Vogler, M., Durr, K., Jovanovic, M., Debatin, K. M. and Fulda, S. (2007) Regulation of TRAIL-induced apoptosis by XIAP in pancreatic cancer cells. Oncogene 26, 248-257.
12. L protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor- mediated apoptosis. Oncogene 19, 5477-5486.
13. L interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc. Natl. Acad. Sci. USA 95, 4386-4391.
14. Li, X., Ding, X. and Adrian, T. E. (2003) Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas 27, 174-179.
15. Tong, W. G., Ding, X. Z., Witt, R. C. and Adrian, T. E. (2002) Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol. Cancer Ther. 1, 929-935.
16. L antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int. J. Cancer 94, 268-274.
17. Shi, X., Liu, S., Kleeff, J., Friess, H. and Büchler, M. W. (2002) Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62, 354-362.
18. Xu, Z. W., Friess, H., Büchler, M. W. and Solioz, M. (2002) Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother. Pharmacol. 49, 504-510.
19. Baell, J. B. and Huang, D. C. (2002) Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem. Pharmacol. 64, 851-863.
20. Krueger, A., Baumann, S., Krammer, P. H. and Kirchoff, S. (2001) FLICE-inhibitory proteins: Regulators of death receptor-mediated apoptosis. Mol. Cell Biol. 21, 8247-8254.
21. Kim, Y., Suh, N., Sporn, M. and Reed, J. C. (2002)An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277, 22320-22329.
22. Kataoka, T., Budd, R. C., Holler, N., Thorne, M., Martinon, F., Irmler, M., Burns, K., Hahne, M., Kennedy, N., Kovacsovics, M. and Tschopp J. (2000) The caspase-8 inhibitor FLIP promotes activation of NFκB and Erk signaling pathways. Curr. Biol. 10, 640-648.
23. Bharti, A. C. and Aggarwal, B. B. (2002) Nuclear factor-κ-B and cancer: Its role in prevention and therapy. Biochem. Pharmacol. 64, 883-888.
24. Deveraux, Q. L. and Reed, J. C. (1999) IAP family proteins-suppressors of apoptosis. Genes Dev. 13, 239-252.
25. Retzer-Lidl M., Schmid, R. M. and Schneider G. (2007) Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int. J. Cancer. 121, 66-75.
26. Chang, Q., Qin, R., Huang, T., Gao J. and Feng, Y. (2006) Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas 32, 297-305.
27. Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T. and Reed, J. C. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-5320.
28. Bhanot, U., Heydrich, R., Moller, P. and Hasel, C. (2006) Survivin expression in pancreatic intraepithelial neoplasia (PanIN): Steady increase along the developmental stages of pancreatic ductal adenocarcinoma. Am. J. Surg. Pathol. 30, 754-759.
29. Shrikhande, S. V., Kleeff, J., Kayed, H., Keleg, S., Reiser, C., Giese, T., Büchler, M. W., Esposito, I. and Friess, H. (2006) Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance in pancreatic cancer cells. Anticancer Res. 26, 3265-3273.
30. Li, Y., Jian, Z., Xia, K., Li, X., Lv, X., Pei, H., Chen, Z. and Li J. (2006) XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 32, 288-296.
31. Guan, H. T., Xue, X. H., Dai, Z. J., Wang, X. J., Li, A. and Qin, Z. Y. (2006) Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. World J. Gastroenterol. 12, 2901-2907.
32. Lopes, R. B., Gangeswaran, R., McNeish, I. A., Wang, Y. and Lemoine, N. R. (2007) Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int. J. Cancer. 120, 2344-2352.
33. Karikari, C. A., Roy, I., Tryggestad, E., Feldmann, G., Pinilla, C., Welsh, K., Reed, J. C., Armour, E. P., Wong, J., Herman, J., Rakheja, D. and Maitra, A. (2007) Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol. Cancer Ther. 6, 957-966.
34. Verhagan, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J. and Vaux, D. L. (2000) Identification of DIABLO., a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43-53.
35. Arnt, C. R., Chiorean, M. V., Heldebrant, M. P., Gores, G. J. and Kaufmann, S. H. (2002) Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP in situ. J. Biol. Chem. 277, 44236-44243.
36. Satoh, K., Kaneko, K., Hirota, M., Toyota, T. and Shimosegawa, T. (2000) The pattern of CPP32/caspase-3 expression reflects the biological behavior of the human pancreatic duct cell tumors. Pancreas 21, 532-537.
37. Roy, S., Bayly, C. I., Gareau, Y., Houtzager, V. M., Kargman, S., Keen, S. L., C., Rowland, K., Seiden, I. M., Thornberry, N. A. and Nicholson, D. W. (2001) Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc. Natl. Acad. Sci. USA 98, 6132-6137.
38. Putt, K. S., Chen, G. W., Pearson, J. M., Sandhorst, J. S., Hoagland, M. S., Kwon, J-T., Hwang, S-K., Jin, H., Churchwell, M. I., Cho, M-H., Doerge, D. R., Helferich, W. G. and Hergenrother, P. J. (2006) Small-molecule activation of pro-caspase-3 to caspase-3 as a personalized anticancer strategy. Nat. Chem. Biol. 2, 543-550.
39. Hruban, R. H., van Mansfeld, A. D., M., Offerhaus, G. J., van Weering, D. H., Allison, D. C., Goodman, S. N., Kensler, T. W., Bose, K. K., Cameron J. L. and Bos J. L. (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization, Am. J. Pathol. 143, 545-554.
40. Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., Vessella, R. L. and Neubauer, B. L. (2000) Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27KIP1 expression. J. Biol. Chem. 275, 24500-24505.
41. L levels in vivo. J. Exp. Med. 191, 1721-1734.
42. Gilmore, A. P., Valentjin, A. J., Wang, P., Ranger, A. M., Bundred, M., O'Hare, M. J., Wakeling, A., Korsmeyer, S. J. and Streuli, C. H. (2002) Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J. Biol. Chem. 277, 27643-27650.
43. Kermer, P., Ankerhold, R., Klocker, N., Krajewski, S., Reed, J. C. and Bahr, M. (2000) Caspase-9: Involvement in secondary death of axotomized rat retinal ganglion cells in vivo. Brain Res. Mol. Brain Res. 85, 144-150.
44. Ng, S. S., W., Tsao, M. S., Chow, S. and Hedley, D. W. (2000) Inhibition of phophatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 60, 5451-5455.
45. Ng, S. S., Tsao, M. S., Nicklee, T. and Hedley, D. W. (2001) Wortmannin inhibits Pkb/Akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res. 7, 3269-3275.
46. Baker, C. H., Trevino, J. G., Summy, J. M., Zhang, F., Caron, A., Nesbit, M., Gallick, G. E. and Fidler, I. J. (2006) Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice. Int. J. Oncol. 29, 125-138.
47. Korc, M., Chandraseker, B., Yamanaka, Y., Friess, H., Büchler, M., and Berger, H. G. (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the level of epidermal growth factor and transforming growth factor alpha. J. Clin. Invest. 90, 1352-1360.
48. Salabat, M. R., Ding, X. Z., Flesche, J. B., Ujiki, M. B., Robin, T. P., Talamonti, M. S., Bell, R. H. and Adrian, T. E. (2006) On the mechanisms of 12-otetradecanoylphorbol-13-acetate-induced growth arrest in pancreatic cancer cells. Pancreas 33,148-155.
49. Miura JWiener, H. HWright LSaba, S. GYim DFein APKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL onmitochondria and induces apoptosis. Mol. Cell 21, 481-493.
50. Moore, M. J., Goldstein, D., Hamm, J., Kotecha, J., Gallinger S., Au, H. J., Nomikos, D., Ding, K., Ptaszynski, M. and Parulekar, W. (2005) Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J. Clin. Oncology 23 (Suppl.), 1.
51. Tang, P. A., Tsao, M. S. and Moore, M. J. (2006) A review of erlotinib and its clinical use. Expert. Opin. Pharmacother. 7, 177-193.
52. Kwak, E. L., Jankowski, J., Thayer, S. P., Lauwers, G. Y., Brannigan, B. W., Harris, P. L., Okimoto, R. A., Haserlat, S. M., Driscoll, D. R., Ferry, D., Muir, B., Settleman, J., Fuchs, C. S. et al. (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. 12, 4283-4287.
53. Bianco, C., Giovannetti, E., Ciardiello, F., Mey V., Nannizzi S., Tortora G., Troiani T., Pasqualetti, F., Eckhardt, G., de Liguoro, M., Ricciardi, S., Del Tacca, M. et al. (2006) Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling,with gemcitabine and ionizing radiation against pancreatic cancer. Clin. Cancer Res. 12, 7099-7107.
54. Xiong, H. Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R. A., Deutsch J., Needle M. and Abbruzzese, J. L. (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter Phase II trial. J. Clin. Oncol. 22, 2610-2616.
55. Graeven, U., Kremer, B., Sudhoff, T., Killing, B., Rojo, F., Weber, D., Tillner, J., Unal, C. and Schmiegel, W. (2006) Phase I study of the humanized anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br. J. Cancer 94, 1293-1299.
56. Messersmith, W. A., Hidalgo, M., Carducci, M. and Eckhardt, S. G. (2006) Novel targets in solid tumors: MEK inhibitors. Clin. Adv. Hematol. Oncol. 4, 831-836.
57. Lev-Ari, S., Starr, A., Vexler, A., Karaush, V., Loew, V., Greif, J., Fenig, E., Aderka, D. and Ben-Yosef, R. (2006) Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Res. 26, 4423-4430.
58. Safran, H., Iannitti, D., Ramanathan, R., Schwartz J. D., Steinhoff M., Nauman C., Hesketh P., Rathore R., Wolff R., Tantravahi U., Hughes, T. M., Maia C. et al. (2004) Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress Her-2/neu. Cancer Invest. 22, 706-712.
59. Karin, M. and Lin, A. (2002) NF-κBat the crossroads of life and death. Nat. Immunol. 3, 221-22.
60. Arlt, A., Vorndamm, J., Breitenbroich, M., Folsch, U. R., Kalthoff, H., Schmidt, W. E. and Schäfer, H. (2001) Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20, 859-868.
61. Li, Y., Ahmed, F., Ali, S., Philip, P. A., Kucuk, O. and Sarkar, F. H. (2005) Inactivation of nuclear factor κB by soy isoflavone genestein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 65, 6934-6942.
62. Takahashi, H., Funahashi, H., Sawai, H., Matsuo, Y., Yamamoto, M., Okada, Y., Takeyama, H. and Manabe, T. (2007) Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway. Dig. Dis. Sci. [Epub ahead of print].
63. Chen J., Ouyang, Z. G., Zhang, S. H. and Zhen, Y. S. (2007) Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Oncol. Rep. 17, 1445-1451.
64. Kunnumakkara, A. B., Guha, S., Krishnan, S., Diagaradjane, P., Gelovani J. and Aggarwal, B. B. (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 67, 3853-3861.
65. Wang, Z., Banerjee, S., Li, Y., Rahman, K. M., Zhang, Y. and Sarkar, F. H. (2006) Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB., vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 66, 2778-2784.
66. Wang, Z., Zhang, Y., Banerjee, S., Li, Y. and Sarkar, F. H. (2006) Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106, 2503-2513.
67. Garcea, G., Manson, M. M., Neal, C. P., Pattenden, C. J., Sutton, C. D., Dennison, A. R. and Berry DP. (2007) Glycogen synthase kinase-3 beta; a new target in pancreatic cancer? Curr. Cancer Drug Targets 7, 209-215.
68. Mann, A. P., Verma, A., Sethi, G., Manavathi, B., Wang, H., Fok, J. Y., Kunnumakkara, A. B., Kumar, R., Aggarwal, B. B. and Mehta, K. (2006) Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-{kappa}B in cancer cells:Delineation of a novel pathway. Cancer Res. 66, 8788-8795.
69. Saidi, R. F., Williams, F., Ng, J., Danquah, G., Mittal, V. K., ReMine, S. G. and Jacobs, M. J. (2006) Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines. Am. J. Surg. 191, 358-363.
70. Morton J. P., Mongeau, M. E., Klimstra, D. S., Morris J. P., Lee, Y. C., Kawaguchi Y., Wright, C. V., Hebrok M. and Lewis, B. C. (2007) Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc. Natl. Acad. Sci. USA 104, 5103-5108.
71. Ghaneh, P., Greenhalf, W., Humphreys, M., Wilson, D., Zumstein, L., Lemoine, N. R. and Neoptolemos, J. P. (2001) Adenovirus-mediated transfer of p53 and p16 (INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther. 8, 199-208.
72. Ding, X. Z., Kuszynski, C. A., El-Metwally, T. H. and Adrian, T. E. (1999) Lipoxygenase inhibitors induce apoptosis, morphological changes and carbonic anhydrase expression in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 266, 392-399.
73. Ding, X. Z., Tong, W. G. and Adrian, T. E. (2000) Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 20, 2625-2631.
74. Hennig, R., Ding, X. Z., Tong, W. G., Schneider, M. B., Standop, J., Friess, H., Buchler, M. W., Pour, P. M. and Adrian, T. E. (2002) 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol. 161, 421-428.
75. Hennig R., Grippo P., Ding, X. Z., Rao, S. M., Buchler, M. W., Friess H., Talamonti, M. S., Bell, R. H. and Adrian, T. E. (2005) 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. 65, 6011-6016.
76. Ding, X. Z., Tong, W. G. and Adrian, T. E. (2001) 12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation. Int. J. Cancer 94, 630-636.
77. Ding, X. Z., Tong, W. G. and Adrian, T. E. (2003) Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer. Oncology 65, 285-294.
78. Tong, W. G., Ding, X. Z. and Adrian, T. E. (2002) Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin. Cancer Res. 8, 3232-3242.
79. Hennig, R., Ventura, J., Segersvard, R., Ward, E., Ding, X. Z., Rao, S. M., Jovanovic, B. D., Iwamura, T., Talamonti, M. S., Bell, R. H. and Adrian, T. E. (2005) LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia 7, 417-425.
80. Ding, X. Z. and Adrian, T. E. (2002) Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 25, e71-e76.
81. Ujiki, M. B., Ding, X. Z., Salabat, M. R., Bentrem, D. J., Golkar, L., Milam, B., Talamonti, M. S., Bell, R. H., Iwamura, T. and Adrian, T. E. (2006) Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol. Cancer 5, 76.
82. Park, Y. J., Wen, J., Bang, S., Park, S. W. and Song, S. Y. (2005) [6]-Gingerol induces cell cycle arrest and cell death of mutant p53-expressing pancreatic cancer cells. Yonsei Med. J. 47, 688-697.
83. Dong, M. L., Ding, X. Z., Collin, P. and Adrian, T. E. (2003) A commercial sea cucumber lipid extract, Frondanol-A5 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 27, 378.
84. Ujiki, M. B., Milam B., Ding, X. Z., Roginsky, A. B., Salabat, M. R., Talamonti, M. S., Bell, R. H., Gu W., Silverman, R. B. and Adrian, T. E. (2006) A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Biochem. Biophys. Res. Commun. 340, 1224-1228.